{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:14:56Z","timestamp":1788434096955,"version":"build-2803163510"},"reference-count":216,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA273424"],"award-info":[{"award-number":["R00CA273424"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM121322"],"award-info":[{"award-number":["P20GM121322"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has undergone great advances since the development of the first-generation CAR in the early 1990s. Currently there are seven FDA approved CAR T-cell therapies for the treatment of hematological malignancies, with marked clinical success. However, the application of CAR T-cell therapies to solid tumors, particularly CNS malignancies, provide unique challenges. This review provides historical perspective on CAR T-cell therapy, describes CAR structures and current generations, and details challenges with the application of CAR T-cells to CNS malignancies. In addition, an extensive summary of all clinical trials, as of March 2026, utilizing CAR T-cell therapy for primary and secondary CNS malignancies are provided. Specific attention is given to detailing CAR structure, route of administration, and dosing. Furthermore, outcomes and adverse events for each trial are described for completed studies and studies reporting interim results. As the application of CAR T-cell therapy continues to expand in CNS malignancies, it is imperative that clinical studies provide adequate details on CAR structures, try to more quickly adopt\/act on preclinical successes, and seek novel application strategies to advance growth in the field.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1891659","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:19:35Z","timestamp":1788430775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T-cells for the treatment of CNS malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Caleb A.","family":"Kisamore","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Owolabi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]},{"name":"Department of Medical Oncology, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire O.","family":"Kisamore","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]},{"name":"Department of Medical Oncology, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"William H.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]},{"name":"Department of Medical Oncology, West Virginia University Cancer Institute, West Virginia University","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"Frontiers | From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification - PubMed","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6144","article-title":"Circulating tumor dna as measurable residual disease in aggressive b-cell lymphoma","volume":"11","author":"Roschewski","year":"2025","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor t cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR\u2010T therapy for treatment of solid tumor in clinical trials: a meta\u2010analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis Markers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188930","article-title":"Time to abandon CAR-T monotherapy for solid tumors","volume":"1878","author":"Yin","year":"2023","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/INMD.20230047","article-title":"CAR\u2010T\u2010cell products in solid tumors: Progress, challenges, and strategies","volume":"2","author":"Qian","year":"2024","journal-title":"Interdiscip Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/exp.20210058","article-title":"Adoptive cell therapy for cancer treatment","volume":"3","author":"Du","year":"2023","journal-title":"Exploration"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T Cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase t cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor t cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.02.024","article-title":"Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments","volume":"26","author":"Nix","year":"2024","journal-title":"Cytotherapy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Dejenie","year":"2022","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2022.100035","article-title":"Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review","volume":"4","author":"Ahmad","year":"2022","journal-title":"Adv Cancer Biol - Metastasis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.16.1.557","article-title":"Secretory protein trafficking and organelle dynamics in living cells","volume":"16","author":"Lippincott-Schwartz","year":"2000","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.09.044","article-title":"Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif","volume":"135","author":"Xu","year":"2008","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for car t-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel Anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"Cells expressing CD19\/CD20 Bispecific chimeric antigen receptors prevent antigen escape by Malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02376-y","article-title":"Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells","volume":"68","author":"Koristka","year":"2019","journal-title":"Cancer Immunology Immunotherapy"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.11.003","article-title":"A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells","volume":"23","author":"Bister","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00507","article-title":"Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional car-t cells co-expressing a suicide gene","volume":"9","author":"Casucci","year":"2018","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u2018spacer\u2019 domain in the extracellular moiety of chimeric antigen receptors avoids \u2018off-target\u2019 activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335424","article-title":"Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic","volume":"15","author":"Smirnov","year":"2024","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"biomark Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado2054","article-title":"Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains","volume":"10","author":"Barbera","year":"2025","journal-title":"Sci Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01712-8","article-title":"CAR T cells: engineered immune cells to treat brain cancers and beyond","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103525","article-title":"CARs: Beyond T cells and T cell-derived signaling domains","volume":"21","author":"Sievers","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)01194-7","article-title":"The organizing principle in the formation of the T cell receptor-CD3 complex","volume":"111","author":"Call","year":"2002","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12008","article-title":"Non-catalytic tyrosine-phosphorylated receptors","volume":"250","author":"Dushek","year":"2012","journal-title":"Immunol Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/stke.3772007re2","article-title":"The expanding role for ITAM-based signaling pathways in immune cells","volume":"2007","author":"Abram","year":"2007","journal-title":"Science's STKE Signal Transduction Knowledge Environ"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp Biol Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary t lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051050","article-title":"CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus","volume":"13","author":"Textor","year":"2021","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Trans Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors","volume":"95","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063037","article-title":"Engineering T cell function using chimeric antigen receptors identified using a dna library approach","volume":"8","author":"Duong","year":"2013","journal-title":"PloS One"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125423","article-title":"Third-Generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of car t cells in treated patients","volume":"134","author":"Schubert","year":"2019","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0200","article-title":"Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell FAS\u2013FASL-dependent AICD","volume":"3","author":"K\u00fcnkele","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28\u2013OX40 \u201cSuper-stimulation","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T Cells releasing IL-18 convert to t-bethigh foxo1low effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade0156","article-title":"Multidimensional control of therapeutic human cell function with synthetic gene circuits","volume":"378","author":"Li","year":"2022","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell\u2013mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005187","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of neuroblastoma by T Cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.08.005","article-title":"Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells","volume":"22","author":"\u0160tach","year":"2020","journal-title":"Cytotherapy"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in prostate cancer eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J Transl Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of tumor immune inhibition using a chimeric cytokine receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.127951","article-title":"Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4","volume":"285","author":"Wilkie","year":"2010","journal-title":"J Biol Chem"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0896","article-title":"A chimeric GM-CSF\/IL18 receptor to sustain CAR T-cell function","volume":"11","author":"Lange","year":"2021","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.005","article-title":"CD28-\u03b6 CAR T Cells Resist TGF-\u03b2 repression through IL-2 Signaling, which can be mimicked by an engineered IL-7 autocrine loop","volume":"26","author":"Golumba-Nagy","year":"2018","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112667","article-title":"Systematic review of available CAR-T cell trials around the world","volume":"14","author":"Barros","year":"2022","journal-title":"Cancers"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109442","article-title":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","volume":"113","author":"Yuti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-811161-1.00001-3","article-title":"Overview of metastatic disease of the central nervous system","volume":"149","author":"Nolan","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.9077","article-title":"CSF tumor dna genotyping and survival among patients with cns metastases","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.07.005","article-title":"Brain metastasis in de novo stage IV breast cancer","volume":"71","author":"He","year":"2023","journal-title":"Breast"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival among patients with advanced skin, renal, and lung cancer treated with Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115253","article-title":"Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015\u20132022)","volume":"217","author":"Pedersen","year":"2025","journal-title":"Eur J Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.12.11","article-title":"Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience","volume":"8","author":"Fountzilas","year":"2017","journal-title":"J Gastrointestinal Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3171\/2018.8.JNS182100","article-title":"Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases","volume":"132","author":"Juloori","year":"2019","journal-title":"J Neurosurg"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J Neuro-Oncology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.08.004","article-title":"Central nervous system metastases","volume":"36","author":"Nieblas-Bedolla","year":"2022","journal-title":"Hematology\/Oncology Clinics North America"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01249-0","article-title":"Major features of the 2021 WHO classification of CNS tumors","volume":"19","author":"Smith","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7462","article-title":"The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know","volume":"43","author":"Osborn","year":"2022","journal-title":"Am J Neuroradiology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33918","article-title":"Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system","volume":"128","author":"Gritsch","year":"2022","journal-title":"Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-04944-y","article-title":"Cancers of the brain and central nervous system: global patterns and trends in incidence","volume":"172","author":"Filho","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05164-0","article-title":"Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022 - PubMed","volume":"175","author":"Kim","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"mAbs"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-026-00760-2","article-title":"Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain","volume":"23","author":"Gampa","year":"2026","journal-title":"Fluids Barriers CNS"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0228","article-title":"Reversing chemokine\/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells","volume":"14","author":"Zhang","year":"2022","journal-title":"Immunotherapy"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunotherapy"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189155","article-title":"Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors","volume":"1879","author":"Wachholz","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020079","article-title":"Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming","volume":"32","author":"Klabukov","year":"2025","journal-title":"Curr Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00086","article-title":"The role of the extracellular matrix in cancer stemness","volume":"7","author":"Nallanthighal","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol Ther"},{"key":"B124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.ccr-17-2041","article-title":"Regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2+ breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi Bryan","year":"2024","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090725","article-title":"State of the art in CAR-T cell therapy for solid tumors: is there a sweeter future","volume":"13","author":"Amor\u00f3s-P\u00e9rez","year":"2024","journal-title":"Cells"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41571-024-00885-z","article-title":"IL-13R\u03b12-targeted CAR T cells show promise in patients with recurrent high-grade gliomas","volume":"21","author":"Killock","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-023-01175-5","article-title":"Structural insights into the activation and inhibition of CXC chemokine receptor 3","volume":"31","author":"Jiao","year":"2024","journal-title":"Nat Struct Mol Biol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.07.003","article-title":"CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells","volume":"22","author":"Li","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-247809","article-title":"Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond","volume":"115","author":"Aldinucci","year":"2010","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41421-022-00403-4","article-title":"Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3","volume":"8","author":"Shao","year":"2022","journal-title":"Cell Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0125-1","article-title":"Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine\/CX3CL1 expressing tumors: importance of the chemokine gradient","volume":"4","author":"Siddiqui","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e5","article-title":"Tissue-specific role of CX3CR1 expressing immune cells and their relationships with human disease","volume":"18","author":"Lee","year":"2018","journal-title":"Immune Netw"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.immuni.2018.10.007","article-title":"Circadian expression of migratory factors establishes lineage-specific signatures that guide the homing of leukocyte subsets to tissues","volume":"49","author":"He","year":"2018","journal-title":"Immunity"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64861-6","article-title":"Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.10.011","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011382","article-title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","volume":"13","author":"De Sostoa","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1757360","article-title":"Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model","volume":"9","author":"Murty","year":"2020","journal-title":"OncoImmunology"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032020","article-title":"The tumor immune microenvironment in primary cns neoplasms: a review of current knowledge and therapeutic approaches","volume":"24","author":"Kalluri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40982-8","article-title":"PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation","volume":"14","author":"Linnerbauer","year":"2023","journal-title":"Nat Commun"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177141","article-title":"Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment","volume":"9","author":"Hatae","year":"2024","journal-title":"JCI Insight"},{"key":"B160","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/s1470-2045(21)00353-3","article-title":"CAR T-cell therapy for solid tumours","volume":"22","author":"Oncology","year":"2021","journal-title":"Lancet Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.cd-24-1465","article-title":"Evolving CAR T-cell therapy to overcome the barriers in treating pediatric central nervous system tumors","volume":"15","author":"Timpanaro","year":"2025","journal-title":"Cancer Discov"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04222-w","article-title":"CAR-T cells immunotherapy in the treatment of glioblastoma","volume":"74","author":"Kr\u00f3likowska","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2017","journal-title":"Neuro-Oncology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor\u2013transduced T Cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunotherapy"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14121220","article-title":"CAR-T Cells for the treatment of central nervous system tumours: known and emerging neurotoxicities","volume":"14","author":"Palazzo","year":"2024","journal-title":"Brain Sci"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Advances in the mechanisms and management of CAR T-cell toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"PNAS"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028964","article-title":"Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy","volume":"146","author":"Kaulen","year":"2025","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113455","article-title":"Development of inducible CD19-CAR T cells with a tet-on system for controlled activity and enhanced clinical safety","volume":"19","author":"Gu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.83","article-title":"An improved bicistronic CD20\/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy","volume":"18","author":"Vogler","year":"2010","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-Cell Malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Invest"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad002","article-title":"Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival","volume":"25","author":"Ellingson","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-O11","article-title":"Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial","volume":"3","author":"Ahmed","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.03.047","article-title":"Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse","volume":"189","author":"Gattinoni","year":"2026","journal-title":"Cell"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"B193","article-title":"Central nervous system tumours","volume-title":"Central Nervous System Tumours","year":"2021"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuo-Oncology"},{"key":"B195","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/neuonc\/noae144.226","article-title":"P12.13.B locoregional bi-specific CAR-T cells targeting CD44 and CD133 in recurrent glioblastoma: the first in-human clinical trial results","volume":"26","author":"Zhai","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B196","article-title":"A phase 1 study of B7H3 CAR-T cells aministered intracranially in recurrent glioblastoma","author":"Li","year":"2025"},{"key":"B197","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2062","article-title":"Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM","author":"Zhang","year":"2024"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102302","article-title":"Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety","volume":"6","author":"Barish","year":"2025","journal-title":"Cell Rep Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1434464","article-title":"Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma","volume":"7","author":"Suryadevara","year":"2018","journal-title":"Oncoimmunology"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf195","article-title":"Targeting TGF\u03b2 docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma","volume":"27","author":"Wu","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B204","doi-asserted-by":"publisher","first-page":"S456","DOI":"10.1016\/j.annonc.2025.08.1238","article-title":"663MO phase I trial of an IL13R\u03b12-targeted CAR-T cell therapy for recurrent Malignant glioma: clinical results and pharmacokinetics","volume":"36","author":"Gwak","year":"2025","journal-title":"Ann Oncol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694941","article-title":"First-in-human trial of EphA2-redirected CAR Tccells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2006","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)","volume":"42","author":"Chukwueke","year":"2024","journal-title":"J Clin Oncol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"viii88","DOI":"10.1093\/neuonc\/noae165.0348","article-title":"CTIM-15. Locoregional administration of B7-H3-CAR T cells expressing 41BB ligand for pediatric patients with primary CNS tumors: preliminary results from a phase I study","volume":"26","author":"Bertrand","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1880","article-title":"GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma","volume":"30","author":"Ciccone","year":"2024","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3454977\/v1","article-title":"Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13Ra2-targeting CAR T cells: an interim analysis","author":"Wang","year":"2023","journal-title":"Res Square"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL-7 receptor promotes durable tumor elimination by tumor redirected T-cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf064","article-title":"Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: results of the completed BrainChild02 phase 1 clinical trial","volume":"27","author":"Gust","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2533","article-title":"Targeting cancer leptomeningeal metastasis with allogeneic chimeric antigen receptor \u03b3\u03b4 T-cell therapy","volume":"43","author":"Ma","year":"2025","journal-title":"J Clin Oncol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"v115","DOI":"10.1093\/neuonc\/noaf201.0464","article-title":"CTIM-07. A phase 1 study of intraventricularly administered autologous her2-targeting chimeric antigen receptor T cells (HER2-CAR T cells), with and without lymphodepletion, in HER2-positive breast cancer patients with recurrent brain and\/or leptomeningeal metastases","volume":"27","author":"Portnow","year":"2025","journal-title":"Neuro-Oncology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1891659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:19:38Z","timestamp":1788430778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1891659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":216,"alternative-id":["10.3389\/fimmu.2026.1891659"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1891659","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1891659"}}